Globus Medical, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Unless otherwise stated, financial figures below are in U.S. dollars. The September 1, 2023 acquisition of NuVasive materially affects comparability: Q3 results include NuVasive for one month, and prior periods do not include it.
Business context and results
Globus develops and sells medical devices and services for musculoskeletal conditions, including spine and orthopedic implants, enabling technologies, and neuromonitoring. It reports one operating segment. Management attributed sales growth to NuVasive, increased spine product sales, and greater enabling-technology sales volume.
- Q3 net sales: $383.6 million, up 51.0% from $254.1 million. U.S. sales were $309.3 million (+42.5%); international sales were $74.3 million (+100.2%).
- Q3 by product category: Musculoskeletal Solutions $347.5 million; Enabling Technologies $27.7 million; Neuromonitoring Services $8.5 million. The neuromonitoring category includes NuVasive results after acquisition.
- Q3 profitability: Gross profit was $248.2 million, with a 64.7% gross margin versus 74.2% a year earlier. Operating income was $0.4 million (0.1% margin), versus $59.7 million (23.5%). Net income was $1.0 million, or $0.01 per diluted share, versus $47.4 million, or $0.47.
- Nine-month net sales: $951.9 million, up 27.2% from $748.3 million. Gross profit was $669.3 million (70.3% margin), operating income $123.0 million (12.9% margin), and net income $107.8 million ($0.98 diluted EPS). Year-earlier margins were 74.2%, 23.2%, and 18.7%, respectively.
Cash flow, balance sheet and financing
- Nine-month operating cash flow: $138.8 million, compared with $114.5 million in 2022. Investing cash flow was a use of $17.6 million; financing cash flow provided $5.4 million. Cash increased $129.2 million to $279.6 million.
- Liquidity at September 30: Cash and equivalents were $279.6 million and marketable securities totaled $465.3 million ($189.3 million short-term and $276.0 million long-term). Current assets were $1.917 billion and current liabilities $428.7 million.
- Debt and credit: The company recorded $409.7 million of senior convertible notes, with $450 million principal due March 15, 2025 and a 0.375% coupon. It also established an unsecured revolving facility of up to $400 million, maturing September 2028; no amount was drawn at quarter-end, and the company reported covenant compliance.
- Working capital and acquired assets: Inventory was $905.0 million, up from $299.0 million at year-end 2022; accounts receivable was $494.1 million, up from $213.2 million. The merger contributed a $284.3 million inventory fair-value step-up, of which $19.0 million was expensed in Q3 and $265.3 million remained at quarter-end.
Merger, changes and unusual items
- NuVasive became a wholly owned subsidiary on September 1. The preliminary purchase price was $2.604 billion, including approximately $2.154 billion of Globus stock consideration; about 39.8 million Class A shares were issued. Preliminary goodwill was $924.2 million and acquired intangible assets were valued at $1.222 billion. Purchase accounting remains subject to measurement-period adjustments.
- Q3 acquisition-related costs were $45.6 million, compared with a $0.7 million benefit in the prior-year quarter. Nine-month costs were $52.7 million, versus a $1.8 million benefit. These included merger, integration and transaction-related items and changes in contingent consideration fair value. Higher acquired-intangible amortization and inventory step-up expense also weighed on reported margins.
- Unaudited pro forma results assuming NuVasive had been acquired at the start of each comparison period showed sales of $585.5 million versus $549.4 million in Q3 2022, and $1.779 billion versus $1.645 billion for the nine months. Pro forma net income was $47.6 million versus a $14.1 million loss for Q3, and $99.5 million versus a $94.9 million loss for nine months; the filing says these figures adjust for acquisition-related costs and they are not reported GAAP results.
- The company expanded its share-repurchase authorization by $350 million in September; no shares were repurchased in the first nine months of 2023. Remaining authorization at quarter-end was $500.8 million.
Outlook, risks and contingencies
- The filing provides no specific numerical revenue, earnings, or margin guidance. Management said cash, marketable securities, and operating cash flow should support liquidity requirements for the foreseeable future, while noting that additional liquidity could be needed as the business strategy is executed.
- Key stated risks include integrating NuVasive and realizing anticipated synergies, retaining employees and surgeon customers, integration costs and disruption, demand and competition, product development, and healthcare regulation. The company also described risks specific to neuromonitoring services, including malpractice exposure, technology disruption, billing and reimbursement, and healthcare-law compliance.
- A patent-infringement case brought by Moskowitz Family LLC had trial scheduled to begin December 4, 2023. The company had recorded no liability and said it could not determine the outcome or estimate a potential loss range. Management stated that legal matters could materially affect earnings, financial position, or cash flows.
- Management concluded disclosure controls and internal controls were effective, but excluded NuVasive from the internal-control assessment because the acquisition was too recent to assess. NuVasive represented approximately 26% of total assets at September 30.
Important facts for investors to verify
- How much reported sales growth and margin change reflect NuVasive versus underlying organic performance; compare reported and pro forma measures carefully.
- Progress on merger integration, synergies, retention, and recurring integration costs, including how preliminary purchase accounting changes.
- Inventory levels, conversion into sales, and the remaining $265.3 million inventory step-up expense expected to flow through cost of sales.
- Cash generation and working-capital needs, including the sharp increase in inventory and receivables, and the 2025 notes’ maturity and potential dilution.
- Developments in the Moskowitz litigation and other legal, regulatory, neuromonitoring reimbursement, and integration risks.